Genetic Technologies Ltd (GENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genetic Technologies Ltd (GENE) has a cash flow conversion efficiency ratio of -3.096x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.67 Million) by net assets ($1.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genetic Technologies Ltd - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Genetic Technologies Ltd (GENE) financial obligations for a breakdown of total debt and financial obligations.
Genetic Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genetic Technologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LM Funding America Inc
NASDAQ:LMFA
|
-0.063x |
|
Frp Advisory Group Plc
LSE:FRP
|
0.275x |
|
Avira Resources Ltd
AU:AVW
|
-0.168x |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
Triboron International AB (publ)
ST:TRIBO-B
|
0.068x |
|
Opawica Explorations Inc
V:OPW
|
-0.022x |
|
Imagine Lithium Inc
V:ILI
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Genetic Technologies Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Genetic Technologies Ltd from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see GENE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $1.83 Million | $-9.68 Million | -5.288x | -507.08% |
| 2023-06-30 | $11.16 Million | $-9.72 Million | -0.871x | -152.89% |
| 2022-06-30 | $16.43 Million | $-5.66 Million | -0.344x | -17.80% |
| 2021-06-30 | $21.53 Million | $-6.30 Million | -0.292x | +28.38% |
| 2020-06-30 | $13.99 Million | $-5.71 Million | -0.408x | +88.09% |
| 2019-06-30 | $1.77 Million | $-6.07 Million | -3.429x | -186.63% |
| 2018-06-30 | $4.71 Million | $-5.64 Million | -1.196x | -85.73% |
| 2017-06-30 | $10.58 Million | $-6.81 Million | -0.644x | +0.95% |
| 2016-06-30 | $11.88 Million | $-7.73 Million | -0.650x | -27.20% |
| 2015-06-30 | $18.96 Million | $-9.69 Million | -0.511x | +91.50% |
| 2014-06-30 | $1.83 Million | $-10.99 Million | -6.012x | -360.56% |
| 2013-06-30 | $5.76 Million | $-7.52 Million | -1.305x | -144.99% |
| 2012-06-30 | $14.40 Million | $-7.67 Million | -0.533x | -262.57% |
| 2011-06-30 | $6.81 Million | $2.23 Million | 0.328x | +143.55% |
| 2010-06-30 | $5.72 Million | $-4.30 Million | -0.753x | -115.70% |
| 2009-06-30 | $17.49 Million | $-6.10 Million | -0.349x | -1815.27% |
| 2008-06-30 | $20.83 Million | $423.68K | 0.020x | -84.38% |
| 2007-06-30 | $16.90 Million | $2.20 Million | 0.130x | +138.82% |
| 2006-06-30 | $18.27 Million | $-6.13 Million | -0.335x | -15.98% |
| 2005-06-30 | $22.75 Million | $-6.58 Million | -0.289x | -9.13% |
| 2004-06-30 | $17.07 Million | $-4.52 Million | -0.265x | -627.25% |
| 2003-06-30 | $27.28 Million | $-993.71K | -0.036x | +65.80% |
| 2002-06-30 | $31.14 Million | $-3.32 Million | -0.107x | -81.95% |
| 2001-06-30 | $38.07 Million | $-2.23 Million | -0.059x | -39.21% |
| 2000-06-30 | $7.58 Million | $-318.68K | -0.042x | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more